Scholar Rock, LLC

The European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc

For big pharma companies who want a major stake in the ballooning obesity market, opportunities to license in a mid-stage asset are dwindling. Roche claimed one of the top unlicensed candidates on 12

“If I think of my well-functioning development machine as let’s say a V12 engine with 12 cylinders, cylinders four, five, six and seven and at different times eight are in Hyderabad.” That’s how Novar

The European Medicines Agency was this week deciding whether the planned EU marketing authorization applications (MAAs) for three investigational products deserved accelerated assessments – apitegroma